Department of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, ROC.
College of Medicine, Tzu-Chi University, Hualien, Taiwan, ROC.
PLoS One. 2022 Nov 21;17(11):e0278040. doi: 10.1371/journal.pone.0278040. eCollection 2022.
Myelodysplastic syndrome (MDS) is a heterogeneous hematopoietic stem cell disorder with thrombocytopenia. Flow cytometric immunophenotyping of blood cells has been instrumental in diagnosis as co-criteria, but the data regarding platelets remains lacking. This study aims to determine if there is a difference in surface antigen levels on platelets by comparing surface antigen levels in MDS patients and healthy control subjects. Concurrently, as flow cytometric gating can reveal the diameter of cells, this study will investigate differences in giant platelet percentage by comparing these percentages in high- and low-risk MDS patients.
Twenty newly diagnosed MDS patients were enrolled in this study. Platelet surface antigen levels were determined by measuring the binding capacity of antibodies with flow cytometry.
Platelets of MDS patients were shown to have a lower level of CD61 and higher levels of CD31 and CD36 than healthy controls. Judged by forward scatter (FSC), MDS patients' platelets appeared to be larger than those of healthy control subjects, whereas the MFI adjusted by diameter (MFI/FSC ratio) of CD31, CD41a, CD42a, CD42b and CD61 on platelets were lower in MDS patients than in healthy control subjects. There was a significant quantity of giant platelets found in MDS patients, and the high-risk MDS patients tended to have a higher percentage of giant platelets than low-risk patients. Conclusions: All the results indicate that MDS patients exhibit a lower antigen presentation (MFI) adjusted by diameter on platelets than healthy controls and the giant platelets detected by flow cytometry might correlate with the condition of MDS.
骨髓增生异常综合征（MDS）是一种异质性造血干细胞疾病，伴有血小板减少症。血细胞流式细胞免疫表型分析已成为诊断标准之一，但关于血小板的相关数据仍较为缺乏。本研究旨在通过比较 MDS 患者和健康对照者的血小板表面抗原水平，确定血小板表面抗原水平是否存在差异。同时，由于流式细胞术门控可以揭示细胞的直径，本研究将通过比较高危 MDS 患者和低危 MDS 患者的巨血小板百分比，研究这些百分比之间的差异。
本研究纳入了 20 例新诊断的 MDS 患者。通过流式细胞术测量抗体的结合能力来确定血小板表面抗原水平。
与健康对照组相比，MDS 患者的血小板 CD61 水平较低，CD31 和 CD36 水平较高。根据前向散射（FSC）判断，MDS 患者的血小板似乎比健康对照组的血小板更大，而 MDS 患者的血小板 CD31、CD41a、CD42a、CD42b 和 CD61 的直径调整后的平均荧光强度（MFI/FSC 比值）则低于健康对照组。MDS 患者中存在大量的巨血小板，且高危 MDS 患者的巨血小板百分比高于低危患者。
所有结果表明，与健康对照组相比，MDS 患者的血小板表面抗原（MFI）呈直径调整后表达水平较低，流式细胞术检测到的巨血小板可能与 MDS 状况相关。
